Protective effects of 10 °C preservation on donor lungs with lipopolysaccharide-induced acute lung injury
- PMID: 39321867
- DOI: 10.1016/j.jtcvs.2024.09.022
Protective effects of 10 °C preservation on donor lungs with lipopolysaccharide-induced acute lung injury
Abstract
Objectives: Hypothermic lung preservation at 10 °C has been recently shown to enhance quality of healthy donor lungs during ischemia. This study aims to show generalizability of the 10 °C lung preservation using an endotoxin-induced lung injury with specific focus on the benefits of post-transplant lung function and mitochondrial preservation.
Methods: Lipopolysaccharide (3 mg/kg) was injected intratracheally in rats to induce lung injury. Injured lungs were flushed with preservation solution and allocated to 3 groups (n = 6 each): minimum cold storage, 6-hour storage on ice (ice), and 6-hour storage at 10 °C (10 °C). Left lungs were transplanted and reperfused for 2 hours. After storage, lung tissue was used to evaluate the effects of hypothermic storage on the mitochondrial function: mitochondrial membrane potential was assessed by JC-1 staining; mitochondrial oxygen consumption was assessed using high-resolution respirometry.
Results: Two hours after reperfusion, the oxygen tension/inspired oxygen fraction ratio from the graft was significantly greater in the 10 °C group than in the Ice group (P = .015), whereas the wet-to-dry weight ratio was significantly lower (P = .041). Levels of interleukin-8 in lung tissues were significantly lower in the 10 °C group than in the Ice group (P = .004). Mechanistically, we noted greater mitochondrial membrane potential and elevated state III respiration in the 10 °C group than in the Ice group (P = .015 and P = .002, respectively), implying higher metabolic activities may be maintained during 10 °C preservation.
Conclusions: Favorable metabolism during 10 °C preservation prevented ischemia-induced mitochondrial damages in injured lungs, leading to better post-transplant outcomes.
Keywords: 10 °C preservation; acute lung injury; lipopolysaccharide; lung transplantation; mitochondrial health.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest Statement M.C., M.L., and S.K. are shareholders of Traferox Technologies Inc. S.K. serves as Chief Medical Officer of Traferox Technologies Inc, receives personal fees from Traferox Technologies Inc, and is an inventor of IP licensed to Traferox Technologies Inc. M.C. serves as Chief Scientific Officer of Traferox Technologies Inc, receives personal fees from Traferox Technologies Inc, and is an inventor of IP licensed to Traferox Technologies Inc. Traferox devices were not used in any part of the study. M.C. and S.K. are consultants for Lung Bioengineering Inc. S.K. is a consultant for Abbott, CareDx, and United Therapeutics. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical